Earl Martin Douglas Sells 29,697 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Posted by Francis Steltz on Aug 25th, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) SVP Earl Martin Douglas sold 29,697 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $2.12, for a total value of $62,957.64. Following the transaction, the senior vice president directly owned 488,267 shares of the company’s stock, valued at $1,035,126.04. This represents a 5.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Allogene Therapeutics Trading Up 6.9%

NASDAQ:ALLO traded up $0.14 during mid-day trading on Tuesday, reaching $2.17. 6,156,169 shares of the stock were exchanged, compared to its average volume of 8,081,610. The business has a fifty day moving average price of $1.98 and a 200 day moving average price of $2.14. Allogene Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $4.46. The firm has a market capitalization of $749.71 million, a PE ratio of -3.24 and a beta of 0.48.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. The business had revenue of $4.64 million during the quarter, compared to analyst estimates of $0.00 million. On average, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -0.59 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on ALLO shares. Citizens Jmp reissued a “market outperform” rating and set a $6.00 target price on shares of Allogene Therapeutics in a research note on Monday, August 17th. Weiss Ratings lowered shares of Allogene Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.30.

Check Out Our Latest Research Report on ALLO

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ALLO. BlackRock Inc. purchased a new position in shares of Allogene Therapeutics in the second quarter worth approximately $62,706,000. Frazier Life Sciences Management L.P. boosted its position in Allogene Therapeutics by 491.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 22,446,668 shares of the company’s stock worth $46,689,000 after acquiring an additional 18,650,000 shares during the period. Primecap Management Co. CA acquired a new stake in Allogene Therapeutics during the 2nd quarter worth about $27,297,000. Goldman Sachs Group Inc. grew its stake in Allogene Therapeutics by 177.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after acquiring an additional 3,747,397 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Allogene Therapeutics in the 2nd quarter valued at about $6,797,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.